Johnson & Johnson and its subsidiaries engages in the research and development, manufacture, and sale of a broad range of products in the healthcare field worldwide. The company’s primary focus is products related to human health and well-being.
Seg…
Analysis
Middle-of-the-road
Johnson & Johnson is a middle-of-the-road business: neither the economics nor the price stand out from the peer group. One caution: reported profits have recently run ahead of actual cash, which we track closely.
The price is fair. You pay 24.1× its owner earnings: the cash an owner could take out each year, which is in the historically fair zone. At today's price, the market is assuming roughly 9% yearly growth; analysts expect 8%. The price, in other words, assumes less than the experts do.
The trajectory is moderate and the balance sheet is sturdy. The company scores 14/20 on our value-creation score: strong value creator.
What to watch: Reported profits have run ahead of actual cash for several periods. As always: this describes the company's numbers; it is not a recommendation.
360° rank · history
1007550250
Jan 202377
79
2023202420252026
All-time high
84
Dec 2025
All-time low
27
Feb 2024
Average rank
52
across all years
Detailed & Historical Ranks
Deep dive into 15 detailed ranks and 3 years of history.
Current202520242023
Price/Sales
48
24
20
20
Price/Earnings
24
48
54
58
Price/Book
17
12
18
20
Dividend Yield
99
90
94
96
Value (overall)
76
59
57
63
Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.